In particular, combining IDO1 inhibitors with PD-1 or CTLA-4 blockade has demonstrated enhanced anti-tumor effects in early phase clinical trials, particularly in melanoma and advanced GBM models [308, 309]. The gene discussed is CTLA4; the disease is glioblastoma.